• Publications
  • Influence
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
BACKGROUND & AIMS Patients with chronic hepatitis C virus (HCV) infection and cirrhosis have a higher risk for liver-related complications and have historically been more difficult to cure thanExpand
  • 150
  • 7
  • PDF
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
BACKGROUND & AIMS Paritaprevir (administered with ritonavir, PTV/r), ombitasvir (OBV), and dasabuvir (DSV) are direct-acting antiviral agents (DAAs) for the treatment of chronic hepatitis C virusExpand
  • 107
  • 7
  • PDF
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
BACKGROUND & AIMS Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of interferon-based therapies. This study evaluatedExpand
  • 113
  • 4
  • PDF
Model-based lamotrigine clearance changes during pregnancy: clinical implication
The objective of the study was to characterize changes in the oral clearance (CL/F) of lamotrigine (LTG) over the course of pregnancy and the postpartum period through a model‐based approachExpand
  • 38
  • 2
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
ABSTRACT The two direct-acting antiviral (2D) regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 andExpand
  • 37
  • 2
Lamotrigine pharmacokinetics following oral and stable‐labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age
The objectives of this study were to investigate the effect of age on pharmacokinetic parameters of lamotrigine (LTG) and estimate parameter variability.
  • 4
  • 2
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies
Direct-acting antiviral agents (DAAs) are established as the standard of care for chronic hepatitis C virus (HCV) infection. One of the newest additions to the HCV arsenal is an oral three-DAAExpand
  • 11
  • 1
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis
IntroductionElagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associatedExpand
  • 10
  • 1
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
The development of direct-acting antiviral (DAA) agents has reinvigorated the treatment of hepatitis C virus infection. The availability of multiple DAA agents and drug combinations has enabled theExpand
  • 27
Drug–Drug Interaction of Omeprazole With the HCV Direct‐Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir
Paritaprevir (administered with low‐dose ritonavir), ombitasvir, and dasabuvir are direct‐acting antiviral agents administered as combination regimens for the treatment of chronic hepatitis C virusExpand
  • 19